Immunotherapy in Breast Cancer
Author:
- 25 May 2016
- journal article
- review article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 39 (6) , 335-345
Abstract
The importance of the tumor microenvironment including immune cell infiltrates in breast cancer has long been recognized. Tumor-infiltrating lymphocytes are prognostic and predictive; however, their prevalence as well as their prognostic and predictive power are subtype-dependent and appear most prominent in aggressive subtypes like triple-negative and HER2-positive disease. The immune responses observed in many cancers are attracted by tumor-associated antigens and, as suggested by recent research, by neoantigens - immunogenic antigens encoded for by non-synonymous mutations. The appealing promise of cancer vaccines has been pursued in breast cancer for over 2 decades; however, despite much effort having been put into vaccine trials, their clinical benefit, with the exception of some encouraging preliminary results, remains disappointing. The main hurdles compromising the efficacy of these vaccination strategies are the difficulties to generate broad and robust immune responses as well as to overcome immune escape mechanisms. The remarkable efficacy of immune checkpoint inhibitors in melanoma and lung cancer has set the ground for a race in the clinical development of numerous agents targeting these immune escape mechanisms in many tumor entities. Early clinical data in metastatic breast cancer suggests at least some clinical activity. This review discusses the current status and future perspectives of immunotherapy in breast cancer.Keywords
This publication has 66 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast CancerJournal of Immunotherapy, 2012
- A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian CancerClinical Cancer Research, 2011
- Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trialJournal of Translational Medicine, 2011
- Leukocyte composition of human breast cancerProceedings of the National Academy of Sciences of the United States of America, 2011
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancersBreast Cancer Research, 2009
- Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic CarcinomaClinical Cancer Research, 2008